The expertise on offer at the facility spans traditional small molecule and emerging modalities such as antibody-drug conjugates (ADCs), oligonucleotides and proteolysis-targeting chimeras (PROTACs), expanding Ofichem’s non-GMP capabilities in early-stage development. 

The site will operate in close coordination with Ofichem’s GMP manufacturing operations in Ter Apel, the Netherlands, describes the company. The acquisition also provides access to a portfolio of more than 40 biotech and mid-sized pharma clients, expanding Ofichem’s reach across the Nordic countries.

“We are proud to have found in Ofichem a reliable and respected partner who shares our values and unwavering focus on customer success,” says Bruce Vielle, CEO of Meribel. “This agreement is not only a positive step for both organizations but especially for the dedicated team and ongoing projects at the Uppsala site. Strategically, the partnership enables Meribel to sharpen its focus on advancing our drug product solutions, an area where we see increasing demand and opportunity. Importantly, we remain committed to ensuring continuity and support for our customers throughout this transition and beyond. We’re confident this collaboration will deliver long-term value for everyone involved.”

The site will be integrated into Ofichem’s matrix structure, aligning under group-level leadership in operations, quality, research and development, and business development, the company states. Looking ahead, Ofichem plans to further grow and expand its early-stage drug substance network, including evaluations of larger-scale GMP manufacturing sites in Europe and North America.